Company Filing History:
Years Active: 2025
Title: Kevin Quinn: Innovator in GLP-1R Agonist Compounds
Introduction
Kevin Quinn is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as glucagon-like peptide-1 receptor (GLP-1R) agonists. His innovative work has the potential to impact the treatment of various diseases and conditions mediated by GLP-1R.
Latest Patents
Kevin Quinn holds 1 patent for his invention titled "Compounds as GLP-IR agonists." This patent provides compounds that may be used as GLP-1R agonists or pharmaceutically acceptable salts thereof. The application also details pharmaceutical compositions containing these compounds, methods for preparing them, and their use in treating or preventing diseases related to GLP-1R.
Career Highlights
Kevin is currently associated with Terns Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is crucial in the pharmaceutical industry, focusing on innovative solutions for health-related challenges.
Collaborations
Kevin collaborates with talented professionals in his field, including Corey Reeves and Christopher T. Jones. Their combined expertise enhances the potential for groundbreaking advancements in pharmaceutical applications.
Conclusion
Kevin Quinn's contributions to the development of GLP-1R agonist compounds exemplify the impact of innovation in the pharmaceutical industry. His work not only showcases his inventive spirit but also holds promise for improving health outcomes.